title: Safety of bone marrow stem cell donation: a review.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) represents the first choice of treatment or an important therapeutic option for several diseases, but it is still marked by morbidity and mortality. In contrast, the donation of hematopoietic stem cells (HSCs) is considered to be a safe procedure. The invaluable ethical source of donation and its central role in transplantation implies that the greatest attention be due to the donor and to the donation process through a serious monitoring protocol for donor safety. Both the Joint Accreditation Committee and the European Committee pay particular attention to the notification of adverse events and adverse reactions. Bone marrow donation is a well established procedure, that has now been performed for >30 years. Although it does not require drug administration, there is hospital admission for 1-3 days with 7-10 days off work. The main risk is related to the anesthesia. Pain in the aspiration area, together with astenia are considered to be the most frequent side effects, as shown by the USA National Marrow Donor Program experience in 1,193 donations. In the European Group for Blood and Marrow Transplantation analysis performed between 1993 and 2005 on 27,770 first HSCTs from bone marrow, only 1 fatal event (pulmonary embolism) and 12 serious adverse events were observed. The most frequent adverse events were cardiac. The incidence of adverse events was significantly lower (P < .05) compared with peripheral blood HSC donors, which confirms the necessity of accurate attention to donor selection and evaluation in bone marrow donation.
authors.affiliation: Bone Marrow Transplantation Unit, Department of Hematology, University of Florence, Italy. a.bosi@dac.unifi.it
authors.forename: A
authors.initials: A
authors.lastname: Bosi
authors.forename: B
authors.initials: B
authors.lastname: Bartolozzi
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D046148:Donor Selection / Q000592:standards*; D004992:Ethics, Medical; D006801:Humans; D007085:Ilium / Q000166:cytology; D016032:Randomized Controlled Trials as Topic; D012449:Safety; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000592:standards*; D013234:Stem Cells / Q000166:cytology; D014019:Tissue Donors / Q000706:statistics & numerical data*